Elngar Enas F, Azzam Mona A, Gobarah Ayman A, Toraih Eman A, Fawzy Manal S, AbdAllah Nouran B
Department of Pediatrics, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
Department of Surgery, School of Medicine, Tulane University, New Orleans, LA, United States.
Front Pediatr. 2022 May 20;10:779511. doi: 10.3389/fped.2022.779511. eCollection 2022.
Neonatal lung disease has a multifaceted etiopathology, including an explosive inflammatory sequence in the immature lung. Complement component 1 Esterase INHibitor (C1INH) is implicated in controlling inflammation in response to infection/injury.
To explore for the first time the association of the rs4926 (Val480Met) variant and circulatory transcript expression levels in the neonates that had evidence of lung disease and the clinic-laboratory data.
A total of 139 unrelated neonates were enrolled in this case-control study. genotyping and expression analyses were done using TaqMan Genotyping and Real-Time qPCR, respectively.
A/A genotype carriers were two times more likely to develop in newborns with lung disease under homozygote (A/A vs. G/G: OR = 2.66, 95%CI = 1.03-6.87, = 0.039) and recessive (A/A vs. G/G-A/G: OR = 2.42, 95%CI = 1.07-6.06, = 0.047) models. Also, a higher frequency of A/A genotype was observed in the patient's cohort complicated with sepsis (44.2 vs. 14.3%, = 0.002). Neonates with lung disease with A variant had more risk for developing sepsis under homozygote (A/A vs. G/G: OR = 5.19, 95%CI = 1.73-15.6, = 0.002), dominant (A/G-A/A vs. G/G: OR = 2.39, 95%CI = 1.02-5.58, = 0.041), and recessive (A/A vs. G/G-A/G: OR = 5.38, 95%CI = 1.86-15.5, < 0.001) models. Regression analysis revealed rs4926A/A genotype as an independent predictor risk factor for sepsis development in cohorts with lung disease (adjusted OR = 4.26, 95%CI = 1.38-13.1, = 0.012). The circulatory transcript was significantly downregulated in neonates with lung disease in whom rs4926A/A carriers had the least expression levels (median: -2.86, IQR: -3.55 to -1.71; < 0.001). ROC curve analysis revealed expression could differentiate between cohorts with/without subsequent development of sepsis, and the discrimination ability was enhanced when combined with circulatory IL-6 and CRP levels (AUC = 0.926, 95%CI = 0.87-0.97).
The rs4926 variant might play an essential role in the susceptibility to neonatal lung disease and could predict sepsis development in this cohort. Furthermore, the circulatory expression levels of this gene were downregulated in the neonatal lung disease cohort, supporting its potential role in the pathophysiology of this disorder, and highlighting its promising role in future targeted therapy.
新生儿肺部疾病具有多方面的病因病理,包括未成熟肺中爆发性的炎症反应。补体成分1酯酶抑制剂(C1INH)参与控制对感染/损伤的炎症反应。
首次探讨rs4926(Val480Met)变异与有肺部疾病证据的新生儿的循环转录本表达水平及临床实验室数据之间的关联。
本病例对照研究共纳入139例无亲缘关系的新生儿。分别采用TaqMan基因分型法和实时定量PCR进行基因分型和表达分析。
在纯合子(A/A与G/G:OR = 2.66,95%CI = 1.03 - 6.87,P = 0.039)和隐性(A/A与G/G - A/G:OR = 2.42,95%CI = 1.07 - 6.06,P = 0.047)模型中,A/A基因型携带者在患有肺部疾病的新生儿中发病的可能性是其他基因型的两倍。此外,在合并败血症的患者队列中观察到A/A基因型的频率更高(44.2%对14.3%,P = 0.002)。在纯合子(A/A与G/G:OR = 5.19,95%CI = 1.73 - 15.6,P = 0.002)、显性(A/G - A/A与G/G:OR = 2.39,95%CI = 1.02 - 5.58,P = 0.041)和隐性(A/A与G/G - A/G:OR = 5.38,95%CI = 1.86 - 15.5,P < 0.001)模型中,携带A变异的患有肺部疾病的新生儿发生败血症的风险更高。回归分析显示,rs4926A/A基因型是患有肺部疾病队列中败血症发生的独立预测危险因素(调整后OR = 4.26,95%CI = 1.38 - 13.1,P = 0.012)。rs4926A/A携带者表达水平最低的患有肺部疾病的新生儿中,循环转录本显著下调(中位数:-2.86,四分位数间距:-3.55至-1.71;P < 0.001)。ROC曲线分析显示,该转录本表达可区分有/无败血症后续发生的队列,与循环IL - 6和CRP水平联合时鉴别能力增强(AUC = 0.926,95%CI = 0.87 - 0.97)。
rs4926变异可能在新生儿肺部疾病易感性中起重要作用,并可预测该队列中的败血症发生。此外,该基因的循环表达水平在新生儿肺部疾病队列中下调,支持其在该疾病病理生理学中的潜在作用,并突出其在未来靶向治疗中的前景。